Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses

Frangos, Jason E.; Kimball, Alexa B.

doi:10.1517/14656566.9.11.2001

Cited by 14 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A study by Frangos and Kimball 53 denoted the effectiveness of short-term (2 weeks) use of clobetasol foam for psoriasis in children. There was no limit on BSA of application.…”

Section: Topical Treatments Topical Corticosteroidsmentioning

confidence: 99%

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

Menter

Cordoro

Davis

et al. 2020

Journal of the American Academy of Dermatology

149

176

View full text Add to dashboard Cite

“…A study by Frangos and Kimball 53 denoted the effectiveness of short-term (2 weeks) use of clobetasol foam for psoriasis in children. There was no limit on BSA of application.…”

Section: Topical Treatments Topical Corticosteroidsmentioning

confidence: 99%

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

Menter

Cordoro

Davis

et al. 2020

Journal of the American Academy of Dermatology

149

176

View full text Add to dashboard Cite

“…Inflammation and pain Acne, androgenetic alopecia UV induced erythma Corticosteroid-responsive dermatoses Flexible membrane vesicles [55] Liposomes [56] Liposomes [57] Skin-lipid liposomes [58] Emollient foam formulation of clobetasol propionate [59] Tamoxifen Hydroxyzine Vitamin D analogues: Calcipotriol, tacalcitol, calcitriol Certain skin disorders Skin Allergy Antiparakeratosis function…”

Section: Musculoskeletal Painmentioning

confidence: 99%

“…Several attempts have been made to incorporate the drug in various colloidal carriers. For instance, the drug has been incorporated into liposomes, [14,59] niosomes, [60][61][62] SLNs, [63] and nanocapsules. [64] These studies have been carried out in various animal models and reported to perform quite well.…”

Section: Dithranolmentioning

confidence: 99%

Novel drug delivery systems in topical treatment of psoriasis: Rigors and vigors

Katare¹,

Raza²,

Singh³

et al. 2010

Indian J Dermatol Venereol Leprol

111

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory skin disorder that may drastically impair the quality of life of a patient. Among the various modes of treatments for psoriasis, topical therapy is most commonly used in majority of patients. The topical formulations based on conventional excipients could serve the purpose only to a limited extent. With the advent of newer biocompatible and biodegradable materials like phospholipids, and cutting-edge drug delivery technologies like liposomes, solid lipid nanoparticles (SLNs), microemulsions, and nanoemulsions, the possibility to improve the efficacy and safety of the topical products has increased manifold. Improved understanding of the dermal delivery aspects and that of designing and developing diverse carrier systems have brought in further novelty in this approach. Substantial efforts and the consequent publications, patents and product development studies on the subject are the matter of interest and review of this article. However, majority of the work is related to the preclinical studies and demands further clinical assessment in psoriasis patients.

show abstract

“…The betamethasone valerate foam formulation was reported to be more effective than betamethasone valerate lotion for treatment of scalp psoriasis whilst clobestol propionate foam and solution formulations were found to be equally as effective. Overall, the foam vehicle has been reportedly associated with better compliance and overall improvements in quality of life [89,90].…”

Section: Topical Foams and Spraysmentioning

confidence: 99%

Topical Dermatological Drug Delivery: Quo Vadis?

Akomeah

2010

CDD

View full text Add to dashboard Cite

Skin disease (dermatological conditions') affects at least one-third of the US population and has been cited as one of the top 15 medical conditions for which prevalence and healthcare spending increased in the last decade. The outcome of topical dermatological drug treatment is significantly influenced by the choice of vehicle or delivery system. Advancements in the life sciences coupled with a growing market for dermatologicals have facilitated the emergence of improved topical formulations and drug delivery systems. The current and emerging approaches of optimizing the topical delivery of dermatological agents (small and large molecules) include the use of chemical enhancers, bio-polymers (e.g. sodium hyaluronate), liposomes, particulate carriers (microspheres and lipid nanoparticles), topical sprays and foams, occlusion (via dressings and patches) topical peels, temperature (heat), iontophoresis and ultrasound. These delivery approaches (when used solely or in a synergistic manner) are a significant improvement over conventional systems (creams, lotions, ointments and pastes) and have the potential to enhance efficacy and tolerability, improve patient compliance (including dermatology life quality), and also fulfil other unmet needs of the topical dermatological market.

show abstract

Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses

Cited by 14 publications

References 27 publications

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

Novel drug delivery systems in topical treatment of psoriasis: Rigors and vigors

Topical Dermatological Drug Delivery: Quo Vadis?

Contact Info

Product

Resources

About